BSR/BHPR Joint Treatment Guidelines for Giant Cell Arteritis
Initial treatment of suspected giant cell arteritis |
|
Uncomplicated (no jaw or tongue claudication or visual changes) |
|
Prednisolone, 40 to 60 mg per day (but not < 0.75 mg per kg) |
|
Complicated |
|
Evolving visual loss or history of amaurosis fugax: intravenous methylprednisolone (Solu-Medrol), 500 mg to 1 g per day for three days, then oral prednisolone, 60 mg per day |
|
Established visual loss: prednisolone, 60 mg per day |
|
Taper (after four weeks of treatment and resolution of symptoms and normalization of ESR/CRP level) |
|
Decrease by 10 mg every two weeks until 20 mg is reached, then decrease by 2.5 mg every two to four weeks until 10 mg is reached, then decrease by 1 mg every one to two months |
|
Antiplatelet therapy |
|
Low-dose aspirin, 81 mg per day (decreases cranial ischemic complications) |
|
Gastrointestinal protection with proton pump inhibitor |
|
Rheumatologists should be involved immediately in the treatment of suspected giant cell arteritis; treatment must be tailored to patient’s symptoms and inflammatory markers followed; in giant cell arteritis, persistence of ESR/CRP elevation may indicate underlying large vessel disease or other diagnosis. |
|
Bone protection |
|
Bisphosphonate, calcium, vitamin D |
BHPR = British Health Professionals in Rheumatology; BSR = British Society for Rheumatology; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate.
References
- https://academic.oup.com/rheumatology/article/49/8/1594/1789465/BSR-and-BHPR-guidelines-for-the-management-of